Table 2.
Treatment and outcome of 52 patients with acute myeloid leukemia reinduced with CLAM
| Parameter | Value |
|---|---|
| Response | |
| CR | 36 (69.2%) |
| CRi | 11 (21.2%) |
| Nonremission | 5 (9.6%) |
| CLAM consolidation | |
| One cycle | 20 (38.4%) |
| Two cycles | 7 (13.4%) |
| Median number of cycles of CLAM consolidation (range) | 1 (0‐2) |
| Allogeneic HSCTa | |
| HLA‐matched sibling donors | 13 (25%) |
| Voluntary‐unrelated donors | 11 (21.1%) |
| Myeloablative conditioning | 17 (32.6%) |
| Reduced‐intensity conditioning | 7 (13.4%) |
| Relapses | 21 (40.4%) |
| Deaths | 17 (32.7%) |
| Deaths from refractory leukemia | 16 (30.8%) |
| Deaths from graft vs host disease | 1 (2%) |
| Deaths within 60 d of the first cycle of CLAM | 0 |
| Survivals | |
| Median overall survival, mo (95% CI) | Not reached |
| 2‐y overall survival | 65.8% |
| Median relapse‐free survival, mo (95% CI) | 23 (17‐26) |
| 2‐y relapse‐free survival | 45.7% |
| Median event‐free survival, mo (95% CI) | 22 (14‐30) |
| 2‐y event‐free survival | 40.2% |
Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; CLAM, clofarabine, cytarabine, and mitoxantrone; CR, complete remission; Cri, complete remission with incomplete hematological recovery; HSCT, hematopoietic stem cell transplantation.
a
22 patients received allogeneic HSCT after CLAM‐induced CR/CRi; 1 patient relapsed after CLAM, received salvage azacitidine and decitabine, and then an allogeneic HSCT; 1 patient not responding to CLAM was treated with decitabine and then received an allogeneic HSCT.